MARGO Framework Caps AI‑Induced Bias in Clinical Trials Below 5% Error Rate

Context Machine learning promises personalized treatment allocation in trials, but adaptive randomization often skews patient characteristics between groups. That imbalance inflates the type I error rate—the chance of incorrectly declaring a treatment effective. Researchers have long needed a method that harnesses AI without compromising statistical rigor.

Key Facts Professor Yeonhee Park of Sungkyunkwan University introduced MARGO (Machine Learning‑Assisted Adaptive Randomization for Group Sequential Trials Based on Overlap Weights). The framework blends predictive AI models with overlap weighting, a technique that re‑balances covariates across treatment arms. Simulations tested four algorithms—Support Vector Machine, K‑Nearest Neighbors, Random Forest, and Multi‑Layer Perceptron—under group‑sequential designs that include interim analyses. Across all scenarios, MARGO kept the overall type I error rate below the 0.05 threshold. Conventional adaptive methods, by contrast, pushed error rates between 0.08 and 0.18, risking false conclusions. MARGO also allocated more patients to the superior treatment and preserved statistical power, meaning true effects remain detectable.

What It Means For trial sponsors, MARGO offers a concrete way to integrate AI while meeting regulatory standards for error control. Patients benefit from higher chances of receiving effective therapies early in the study, addressing ethical concerns about exposing participants to inferior arms. The framework’s compatibility with any machine‑learning model suggests broader applicability beyond the four algorithms tested, potentially extending to genomics‑driven precision medicine. Clinicians should watch for pilot implementations of MARGO in upcoming phase II oncology and cardiology trials. Regulatory bodies may soon reference the method when evaluating adaptive designs that rely on AI. The next step will be real‑world validation to confirm simulation results hold in practice.

*Watch for early trial reports that adopt MARGO and for guidance updates from the FDA on AI‑assisted randomization.*